Copyright
©The Author(s) 2019.
World J Gastrointest Oncol. Aug 15, 2019; 11(8): 622-633
Published online Aug 15, 2019. doi: 10.4251/wjgo.v11.i8.622
Published online Aug 15, 2019. doi: 10.4251/wjgo.v11.i8.622
Figure 1 Detection of Lysine Specific Demethylase 1 mRNA and protein levels in gastric cancer.
A: Quantitative RT-PCR was used to detect expression of Lysine Specific Demethylase 1 (LSD1) mRNA in gastric cancer tissues; B: western blotting was used to detect expression level of LSD1 protein in gastric cancer tissues. aP < 0.05, bP < 0.01.
Figure 2 Survival analysis of relationship between Lysine Specific Demethylase 1 expression level and prognosis of gastric cancer patients.
LSD1: Lysine Specific Demethylase 1.
Figure 3 Reverse transcription polymerase chain reaction and Western blotting detection of interference efficiency of Lysine Specific Demethylase 1-shRNA transfection.
A: LSD1 mRNA expression was detected by reverse transcription polymerase chain reaction; B: protein expression was detected by Western blotting. LSD1: Lysine Specific Demethylase 1.
Figure 4 Effect of downregulating Lysine Specific Demethylase 1 expression on proliferation of MKN-45 cells.
LSD1: Lysine Specific Demethylase 1.
Figure 5 Effect of downregulating Lysine Specific Demethylase 1 expression on the invasiveness of MKN-45 cells (×200).
A: Control group; B: LSD1-shRNA transfection group. LSD1: Lysine Specific Demethylase 1.
Figure 6 Effect of downregulating Lysine Specific Demethylase 1 expression on expression of molecular proteins associated with MKN-45 cell transfer in VEGF-C/PI3K/AKT signaling pathw
- Citation: Pan HM, Lang WY, Yao LJ, Wang Y, Li XL. shRNA-interfering LSD1 inhibits proliferation and invasion of gastric cancer cells via VEGF-C/PI3K/AKT signaling pathway. World J Gastrointest Oncol 2019; 11(8): 622-633
- URL: https://www.wjgnet.com/1948-5204/full/v11/i8/622.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v11.i8.622